IQVIA, Kexing Biopharm Expand Collaboration to Advance Biosimilar Development

IQVIA, a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program.

The collaboration is designed to support Kexing’s global expansion by bringing together IQVIA’s end-to-end capabilities across the development lifecycle. By aligning clinical development, regulatory strategy, advanced analytics and commercialization under a coordinated global approach, the program aims to accelerate biosimilar development for international markets while upholding rigorous standards for quality and scientific integrity.

Furthermore, the collaboration integrates IQVIA’s AI‑enabled clinical trial capabilities to enhance speed, efficiency and confidence in decision-making throughout development. The use of AI across key activities — from protocol design to site identification and study conduct — will help streamline execution and improve overall trial performance.

“Through this collaboration, we are supporting Kexing as it progresses its global biosimilar development efforts,” said Brian Mi, President, Asia Pacific, IQVIA. “IQVIA brings deep biosimilar expertise, global execution capabilities and AI-powered solutions to accelerate Kexing’s global expansion strategy.”

“This strategic collaboration will accelerate Kexing’s internationalization strategy and we are highly confident in its prospects,” said Yanqing Zhao, General Manager, Kexing Biopharm. “IQVIA’s scale, global data resources, AI capabilities, patient insights and clinical expertise will support the optimization of trial design, mitigation of regulatory risk and improvement of overseas registration efficiency.”

Related Insights

Learn about drug patents, exclusivity and biosimilars.